# A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

> **NCT06501196** · PHASE1 · RECRUITING · sponsor: **BlossomHill Therapeutics** · enrollment: 170 (estimated)

## Conditions studied

- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Preleukemia
- Myelodysplastic Syndromes
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** BH-30236
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06501196
- **Lead sponsor:** BlossomHill Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501196, "A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06501196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*